Table 2 PSA response and OS probability over time.

From: Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study

Outcome

Darolutamide (n = 402)

Enzalutamide (n = 409)

Apalutamide (n = 140)

PSA response,a patients with event, n (%)

PSA50

352 (87.6)

338 (82.6)

112 (80.0)

PSA90

262 (65.2)

263 (64.3)

85 (60.7)

PSA <0.2 ng/mL

214 (53.2)

207 (50.6)

68 (48.6)

 

(n = 565)

(n = 609)

(n = 201)

OS,b survival probability, % (95% CI)

12 months

95.9 (94–97)

92.0 (90–94)

94.9 (91–97)

24 months

87.9 (85–91)

78.4 (75–82)

86.0 (80–90)

36 months

77.6 (73–81)

70.5 (66–74)

74.0 (66–81)

Deaths, n (%)

 

104 (18.4)

156 (25.6)

47 (23.4)

  1. ARI androgen receptor inhibitor, OS overall survival, PSA prostate-specific antigen, PSA50 ≥50% reduction in PSA from baseline, PSA90 ≥90% reduction in PSA from baseline.
  2. aPSA response was defined as PSA50, PSA90, or an absolute PSA level of <0.2 ng/mL at any time point during the study. PSA levels <0.2 ng/mL were considered undetectable.
  3. bOS was defined as the time from the index date (first ARI received) to the date of death due to any cause. Death information was collected via a combination of electronic medical records and linked claims data, which derive the death date from health insurance claims, obituary data, and the National Death Index.
Back to article page